Abstract
In the Lancet Haematology, Gina Mazza and colleagues1 on behalf of the Myeloproliferative Neoplasms Research Consortium present their evaluation of the correlation between clinical response as defined by European LeukemiaNet criteria, and symptomatic response as defined by patient-reported questionnaires in patients with essential thrombocythaemia and polycythaemia vera. They performed a post-hoc analysis of data derived from two clinical trials (MPN-RC 111 and MPN-RC 112) in patients with these conditions treated either with pegylated interferon alfa-2a or hydroxyurea.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
